The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Abstract
PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS: Cohorts of patients with metastatic cancer having failed prior therapy entered a phase I trial of rhuMAb VEGF administered by a 90-minute intravenous infusion at doses from 0.1 to 10.0 mg/kg on days 0, 28, 35, and 42. Patients underwent pharmacokinetic sampling on day 0 and had serum samples obtained during the subsequent 28 days. Response assessment was carried out on days 49 and 72. RESULTS: Twenty-five patients with a median Eastern Cooperative Oncology Group performance status of 0 were accrued. There were no grade III or IV adverse events definitely related to the antibody. There were three episodes of tumor-related bleeding. Infusions of rhuMAb VEGF were well tolerated without significant toxicity. Grades I and II adverse events possibly or probably related to study drug included asthenia, headache, and nausea. Pharmacokinetics revealed a linear profile with a half-life of 21 days. There were no objective responses, though 12 patients experienced stable disease over the duration of the study. CONCLUSION: rhuMAb VEGF was safely administered without dose-limiting toxicity at doses ranging up to 10 mg/kg. Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of ≥ 0.3 mg/kg have a half-life similar to that of other humanized antibodies. Subsequent trials will explore rhuMAb VEGF alone and in combination chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins
FERRARA, N., HOUCK, K., JAKEMAN, L., & LEUNG, D. W. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-18 · Cited by 1,655
Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., & Symes, J. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03361-2 · Cited by 989
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★
Casale, T. B., Bernstein, I. L., Busse, W. W., LaForce, C. F., Tinkelman, D. G., Stoltz, R. R., Dockhorn, R. J., Reimann, J., Su, J. Q., & Fick Jr., R. B. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70202-1 · Cited by 326
Kim, K. J., Li, B., Houck, K., Winer, J., & Ferrara, N. (1992) · Growth Factors · doi:10.3109/08977199209023937 · Cited by 306
Fontanini, G., Vignati, S., Boldrini, L., Chinè, S., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., & Bevilacqua, G. (1997) · PubMed · Cited by 306
Cited by
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Self-citationKabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Tsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 549
Herbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 370
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 364
Self-citationTargeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Lu, J.-F., Bruno, R., Eppler, S., Novotny, W., Lum, B., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 350
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Eskens, F. A. L. M., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.015 · Cited by 342
Caldwell, R. B., Bartoli, M., Behzadian, M. A., El‐Remessy, A. E. B., Al‐Shabrawey, M., Platt, D. H., & Caldwell, R. W. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.415 · Cited by 293
Managing Patients Treated with Bevacizumab Combination Therapy
Gordon, M. S., & Cunningham, D. (2005) · Oncology · doi:10.1159/000088481 · Cited by 283
Self-citationl‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth
Oda, K., Hosoda, N., Endo, H., Saito, K., Tsujihara, K., Yamamura, M., Sakata, T., Anzai, N., Wempe, M. F., Kanai, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01386.x · Cited by 273
Rosen, L. S. (2002) · Cancer Control · doi:10.1177/107327480200902s05 · Cited by 268
Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1484 · Cited by 258
Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
Toi, M., Matsumoto, T., & Bando, H. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00556-3 · Cited by 257
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 256
Schwartz, J. D., Schwartz, M., Mandeli, J., & Sung, M. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00873-2 · Cited by 254
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144
“6 mL/d/kg).(45,52,53) Because the individual BW and CL data for bevacizumab were not available, the medians of the actual body weight ranges and/or mean CL values at different dose levels for different species were also explored to avoid potential likely bias introduced by the standard BW.”
BackgroundHuh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Metadata
- Authors
- Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-02-01
- Volume
- 19
- Issue
- 3
- Pages
- 843-850
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145224595
- Cited by
- 913
- References
- 20
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.